HRP20050133A2 - Topical treatment of skin diseases - Google Patents

Topical treatment of skin diseases Download PDF

Info

Publication number
HRP20050133A2
HRP20050133A2 HR20050133A HRP20050133A HRP20050133A2 HR P20050133 A2 HRP20050133 A2 HR P20050133A2 HR 20050133 A HR20050133 A HR 20050133A HR P20050133 A HRP20050133 A HR P20050133A HR P20050133 A2 HRP20050133 A2 HR P20050133A2
Authority
HR
Croatia
Prior art keywords
mono
alkyl
polyunsaturated
aryl
ring members
Prior art date
Application number
HR20050133A
Other languages
English (en)
Croatian (hr)
Inventor
Rundfeldt Chris
Kietzmann Manfred
Hoppmann Joachim
B�umer Wolfgang
Kuss Hildegard
H�Fgen Norbert
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of HRP20050133A2 publication Critical patent/HRP20050133A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20050133A 2002-07-11 2003-07-10 Topical treatment of skin diseases HRP20050133A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39522102P 2002-07-11 2002-07-11
PCT/EP2003/007514 WO2004006920A1 (en) 2002-07-11 2003-07-10 Topical treatment of skin diseases

Publications (1)

Publication Number Publication Date
HRP20050133A2 true HRP20050133A2 (en) 2005-04-30

Family

ID=30115840

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050133A HRP20050133A2 (en) 2002-07-11 2003-07-10 Topical treatment of skin diseases

Country Status (20)

Country Link
US (1) US20040038958A1 (pl)
EP (1) EP1531818A1 (pl)
JP (1) JP2005537262A (pl)
KR (1) KR20050021464A (pl)
CN (1) CN1681500A (pl)
AR (1) AR040647A1 (pl)
AU (1) AU2003254332B2 (pl)
BR (1) BR0312696A (pl)
CA (1) CA2492093A1 (pl)
HR (1) HRP20050133A2 (pl)
IL (1) IL166016A0 (pl)
MX (1) MXPA05000486A (pl)
NO (1) NO20050718L (pl)
NZ (1) NZ537482A (pl)
PL (1) PL375487A1 (pl)
RU (1) RU2005103608A (pl)
TW (1) TW200410690A (pl)
UA (1) UA80711C2 (pl)
WO (1) WO2004006920A1 (pl)
ZA (1) ZA200500108B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1546142A4 (en) 2002-08-29 2007-10-17 Merck & Co Inc INDOLES HAVING ANTIDIABETIC EFFECT
CN100457730C (zh) 2002-08-29 2009-02-04 默克公司 具有抗糖尿病活性的吲哚化合物
WO2004107678A2 (en) * 2003-05-28 2004-12-09 Artimi Ltd Ultra-wideband network, device, device controller, method and data packet for establishing a mesh network and forwarding packets on another channel
EP1713471B1 (en) * 2004-02-06 2012-01-18 MEDA Pharma GmbH & Co. KG Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
ES2413011T3 (es) * 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
JP4961131B2 (ja) * 2004-10-29 2012-06-27 田辺三菱製薬株式会社 皮膚損傷治療剤
TWI339578B (en) * 2004-10-29 2011-04-01 Mitsubishi Tanabe Pharma Corp Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions
EP1863476B1 (en) * 2005-03-16 2016-02-03 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
NZ591969A (en) * 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US7645752B2 (en) * 2006-01-13 2010-01-12 Wyeth Llc Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
AU2007218725B2 (en) 2006-02-21 2011-12-01 Eisai R & D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
US8530654B2 (en) 2007-02-16 2013-09-10 Eisai R&D Management Co., Ltd. Crystals, amorphous substances or salts of methyl N-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl) phenyl] terephthalamic acid
AU2008290000B2 (en) 2007-08-17 2012-05-10 Eisai R & D Management Co., Ltd. Method for producing quinazoline derivative
CA2696793A1 (en) 2007-08-17 2009-02-26 Eisai R&D Management Co., Ltd. Novel preparation for external use
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
CA2962429C (en) 2014-09-29 2023-01-03 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341783A (en) * 1980-07-31 1982-07-27 Lemmon Company Topical use of dyphylline and dyphylline containing compositions
AU6821294A (en) * 1993-04-30 1994-11-21 Rodner R. Winget Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto
PL198983B1 (pl) * 1998-04-28 2008-08-29 Elbion Ag Nowe hydroksyindole, ich zastosowanie jako inhibitorów fosfodiesterazy 4 oraz sposoby ich wytwarzania

Also Published As

Publication number Publication date
AU2003254332B2 (en) 2009-01-08
CA2492093A1 (en) 2004-01-22
CN1681500A (zh) 2005-10-12
AR040647A1 (es) 2005-04-13
MXPA05000486A (es) 2005-07-22
NZ537482A (en) 2006-09-29
TW200410690A (en) 2004-07-01
ZA200500108B (en) 2005-02-23
BR0312696A (pt) 2005-04-26
NO20050718L (no) 2005-04-01
RU2005103608A (ru) 2005-06-27
UA80711C2 (en) 2007-10-25
PL375487A1 (pl) 2005-11-28
US20040038958A1 (en) 2004-02-26
EP1531818A1 (en) 2005-05-25
KR20050021464A (ko) 2005-03-07
IL166016A0 (en) 2006-01-15
JP2005537262A (ja) 2005-12-08
WO2004006920A1 (en) 2004-01-22
AU2003254332A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
HRP20050133A2 (en) Topical treatment of skin diseases
Fischer et al. Vitamin D regulating TGF-β induced epithelial-mesenchymal transition
CN102316932B (zh) 治疗与毛发相关的病况的方法
Zhang et al. Divergent effect of mometasone on human eosinophil and neutrophil apoptosis
Mokry et al. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs
EP2355810B1 (en) Compound for the treatment of psoriasis
JP2014510064A (ja) Ｎｒｆ２活性剤としてのカルコン誘導体
CN107073125A (zh) Cbp/ep300和bet抑制剂用于治疗癌症的用途
PT1815247E (pt) Uso terapêutico de inibidores de farnesiltransferase e métodos para monitorizar a eficácia do mesmo
JP6498195B2 (ja) 代謝疾患を処置するためのｐｐａｒ節約化合物
Ward et al. Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease
US6403831B1 (en) Substituted benzylidene indenyl formamides, acetamides and propionamides
JP2004531514A (ja) 尿失禁の処置のための選択的ｃｏｘ−２阻害剤の使用
Fujii et al. Characterization of a 2, 4-dinitrochlorobenzene-induced chronic dermatitis model in rats
Bäumer et al. AWD 12–281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis
Vital et al. Dexamethasone prevents granulocyte‐macrophage colony‐stimulating factor‐induced nuclear factor‐κB activation, inducible nitric oxide synthase expression and nitric oxide production in a skin dendritic cell line
Bäumer et al. Effects of the phosphodiesterase 4 inhibitors SB 207499 and AWD 12-281 on the inflammatory reaction in a model of allergic dermatitis
JP2015534942A (ja) Ｃｂｐ／カテニン阻害剤を用いる過剰増殖性及び前がん性皮膚病の治療
Hoppmann et al. The phosphodiesterase 4 inhibitor AWD 12–281 is active in a new guinea‐pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice
WO2024092047A1 (en) Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis
CN117396505A (zh) 治疗炎症的方法
CN119097710B (zh) Ape1抑制剂在制备治疗过敏性鼻炎药物中的应用
US20190321322A1 (en) Nrf2 activators for the prevention and/or treatment of axonal degeneration
Ahmad et al. Molecular bases of adipose tissue aging
CN119157880A (zh) 一种6-氨基-1H-吡唑并[3,4-d]嘧啶类JAK3激酶抑制剂在治疗特应性皮炎中的应用

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20070703

Year of fee payment: 5

OBST Application withdrawn